NCT05592990 - A Study to Investigate the Safety, Tolerability and Preliminary Efficacy of NGI226 Microparticles in Patients With Achilles Tendinopathy | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

June 14, 2023

Primary Completion Date

February 24, 2026

Study Completion Date

February 24, 2026

Conditions

Achilles Tendinopathy

Interventions

DRUG

NGI226

NGI226 MP

DRUG

Placebo

Placebo MP

Trial Locations (8)

RECRUITING

Novartis Investigative Site, Berlin

ACTIVE_NOT_RECRUITING

Novartis Investigative Site, Hamburg

COMPLETED

Novartis Investigative Site, Hamburg

RECRUITING

Advanced Research LLC, Deerfield Beach

WITHDRAWN

Novartis Investigative Site, Nantes

RECRUITING

Novartis Investigative Site, Caluire-et-Cuire

RECRUITING

Houston Methodist Hospital, Houston

RECRUITING

Tucson Orthopedic Institute PC, Tucson